AU2001278631A1 - 17-aryl-linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase - Google Patents
17-aryl-linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphataseInfo
- Publication number
- AU2001278631A1 AU2001278631A1 AU2001278631A AU7863101A AU2001278631A1 AU 2001278631 A1 AU2001278631 A1 AU 2001278631A1 AU 2001278631 A AU2001278631 A AU 2001278631A AU 7863101 A AU7863101 A AU 7863101A AU 2001278631 A1 AU2001278631 A1 AU 2001278631A1
- Authority
- AU
- Australia
- Prior art keywords
- group
- modulator
- steroid sulphatase
- compound
- sulphamates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Nutrition Science (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
There is provided a compound of Formula I
wherein X is a ring system; R 1 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; R 2 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; wherein when X is a steroidal structure and both of R 1 and R 2 are sulphamate groups, the steroidal ring system (X) represents an oestrogen; and wherein said compound is capable of inhibiting steroid sulphatase (STS) activity and/or is capable of acting as a modulator of cell cycling and/or as a modulator of apoptosis and/or as a modulator of cell growth. There is also provided a compound of Formula VIII
wherein R 2 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; and wherein said compound is capable of inhibiting steroid sulphatase (STS) activity and/or is capable of acting as a modulator of cell cycling and/or as a modulator of apoptosis and/or as a modulator of cell growth.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0020498 | 2000-08-18 | ||
GBGB0020498.2A GB0020498D0 (en) | 2000-08-18 | 2000-08-18 | Compound |
PCT/GB2001/003692 WO2002016393A1 (en) | 2000-08-18 | 2001-08-17 | 17-aryl-linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001278631A1 true AU2001278631A1 (en) | 2002-03-04 |
Family
ID=9897954
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001278629A Abandoned AU2001278629A1 (en) | 2000-08-18 | 2001-08-17 | Oestrogen-17-sulphamates as inhibitors of steroid sulphatase |
AU2001278638A Abandoned AU2001278638A1 (en) | 2000-08-18 | 2001-08-17 | Thioether-sulphamate steroids as steroid sulphatase inhibitors and anti-cancer compounds |
AU2001278631A Abandoned AU2001278631A1 (en) | 2000-08-18 | 2001-08-17 | 17-aryl-linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001278629A Abandoned AU2001278629A1 (en) | 2000-08-18 | 2001-08-17 | Oestrogen-17-sulphamates as inhibitors of steroid sulphatase |
AU2001278638A Abandoned AU2001278638A1 (en) | 2000-08-18 | 2001-08-17 | Thioether-sulphamate steroids as steroid sulphatase inhibitors and anti-cancer compounds |
Country Status (12)
Country | Link |
---|---|
US (3) | US7067503B2 (en) |
EP (4) | EP1311533A1 (en) |
JP (3) | JP5191079B2 (en) |
AT (1) | ATE428720T1 (en) |
AU (3) | AU2001278629A1 (en) |
CY (1) | CY1109130T1 (en) |
DE (1) | DE60138390D1 (en) |
DK (1) | DK1311532T3 (en) |
ES (1) | ES2323630T3 (en) |
GB (1) | GB0020498D0 (en) |
PT (1) | PT1311532E (en) |
WO (3) | WO2002016392A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040127473A1 (en) * | 1996-12-05 | 2004-07-01 | Reed Michael John | Compound |
GB0020498D0 (en) * | 2000-08-18 | 2000-10-11 | Sterix Ltd | Compound |
GB0113920D0 (en) | 2001-06-07 | 2001-08-01 | Sterix Ltd | Composition |
US8026229B2 (en) | 2001-08-13 | 2011-09-27 | Sterix Limited | Antitumor-active 2-alkoxyestradiol sulfamates |
EP1358882A1 (en) * | 2002-04-30 | 2003-11-05 | Schering Aktiengesellschaft | Use of estriol sulfamate prodrugs for the treatment of autoimmune diseases |
DE10307105A1 (en) * | 2003-02-19 | 2004-09-09 | Schering Ag | Antitumor active 2-substituted 18a-homoestra-1,3,5 (10) -trien-3-yl sulfamate |
GB0306718D0 (en) | 2003-03-24 | 2003-04-30 | Sterix Ltd | Compound |
EP1608671B1 (en) * | 2003-03-24 | 2010-01-06 | Sterix Limited | Oestrogen derivatives as inhibitors of steroid sulphatase |
GB0306717D0 (en) * | 2003-03-24 | 2003-04-30 | Sterix Ltd | Compound |
GB0505541D0 (en) * | 2005-03-17 | 2005-04-27 | Novartis Ag | Organic compounds |
GB0702446D0 (en) * | 2007-02-08 | 2007-03-21 | Sterix Ltd | Composition |
US9284345B2 (en) * | 2007-04-12 | 2016-03-15 | Endorecherche, Inc. | 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators |
CA2698814A1 (en) | 2007-09-17 | 2009-03-26 | Preglem S.A. | Treatment of oestrogen dependant conditions in pre-menopausal women |
US9956226B2 (en) | 2013-02-11 | 2018-05-01 | President And Fellows Of Harvard College | Methods and compounds for the inhibition of cellular proliferation |
ES2514140B1 (en) * | 2013-03-26 | 2015-08-03 | Universidad Pablo De Olavide | Use of the STX64 steroid sulfatase inhibitor for the treatment of aging |
US11548893B2 (en) | 2017-07-15 | 2023-01-10 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
DK132707C (en) * | 1973-07-13 | 1976-07-12 | Schering Ag | ANALOGICAL PROCEDURE FOR THE PREPARATION OF 1,3,16,17-TETRAOXYGENED 8ALFA-OSTRATRIENS |
DE2336432A1 (en) | 1973-07-13 | 1975-01-30 | Schering Ag | 3.17.18-TRIHYDROXY-1.3.5 (10) -OESTRATRIENE |
US3951959A (en) * | 1973-07-13 | 1976-04-20 | Schering Aktiengesellschaft | 1,3-Oxygenated 8α-estratrienes |
DK133051C (en) | 1973-07-13 | 1976-08-16 | Schering Ag | ANALOGICAL PROCEDURE FOR THE PREPARATION OF 1,3-OXYGENATED 8ALFA-OSTRATRIENS |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
EP0096910B1 (en) | 1982-05-19 | 1989-04-19 | Unilever N.V. | Yeast of the genus kluyveromyces modified for the expression of preprothaumatin or its various allelic and modified forms or their maturation forms |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
NZ208806A (en) | 1983-07-06 | 1988-07-28 | Gist Brocades Nv | Genetic engineering of industrial microorganism species: readily-transformable host used as intermediate in transfer of dna to the industrial species; plasmids |
US4885249A (en) | 1984-12-05 | 1989-12-05 | Allelix, Inc. | Aspergillus niger transformation system |
ATE161881T1 (en) | 1985-04-15 | 1998-01-15 | Gist Brocades Nv | USE OF PROMOTORS OF FILAMENTOUS MUSHROOMS |
NO872932L (en) | 1986-07-18 | 1988-01-19 | Gist Brocades Nv | PROCEDURE FOR THE MANUFACTURE OF PROTEINS WITH FACTOR VIVILITY BY MICROBIAL HOSTS, EXPRESSING VECTORS, HOSTING CELLS, ANTIBIOTICS. |
NZ225597A (en) | 1987-07-28 | 1991-08-27 | Gist Brocades Nv | Use of kluyveromyces in the production of chymosin, tpa, hsa and other proteins |
GB9003939D0 (en) | 1990-02-21 | 1990-04-18 | Imperial College | Sulphatase inhibitors |
KR100225087B1 (en) | 1990-03-23 | 1999-10-15 | 한스 발터라벤 | The expression of phytase in plants |
GB9118478D0 (en) * | 1991-08-29 | 1991-10-16 | Imperial College | Steroid sulphatase inhibitors |
US6011024A (en) * | 1991-08-28 | 2000-01-04 | Imperial College Of Science Technology & Medicine | Steroid sulphatase inhibitors |
GB9625334D0 (en) * | 1996-12-05 | 1997-01-22 | Imperial College | Compound |
US6476011B1 (en) * | 1991-08-28 | 2002-11-05 | Sterix Limited | Methods for introducing an estrogenic compound |
GB9118465D0 (en) * | 1991-08-29 | 1991-10-16 | Imperial College | Steroid sulphatase inhibitors |
DE4429397C2 (en) * | 1994-08-09 | 2003-11-20 | Jenapharm Gmbh | Estra-1,3,5 (10) -triene derivatives, processes for their preparation and pharmaceutical compositions containing these compounds |
GB9422777D0 (en) | 1994-11-11 | 1995-01-04 | Imperial College | Assay |
US5723315A (en) | 1996-08-23 | 1998-03-03 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
US5567831A (en) | 1995-08-16 | 1996-10-22 | Duguesne University Of The Holy Ghost | Non-steroidal sulfatase inhibitor compounds and their method of use |
JP2000517297A (en) | 1996-08-07 | 2000-12-26 | ダーウィン・ディスカバリー・リミテッド | Hydroxamic acid derivatives and carboxylic acid derivatives having MMP and TNF inhibitory activities |
EP2065396A1 (en) | 1996-08-30 | 2009-06-03 | Human Genome Sciences, Inc. | Interleukin-19 |
US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
CN1131238C (en) * | 1996-09-12 | 2003-12-17 | 帝国脏器制药株式会社 | 3-substituted-d-homo-1,3,5 (10)-estratriene derivatives |
ES2217428T3 (en) | 1996-09-25 | 2004-11-01 | Ss Pharmaceutical Co., Ltd. | VINILPIRIDINE DERIVATIVES REPLACED AND MEDICINES CONTAINING THEM |
WO1999064013A1 (en) * | 1998-06-10 | 1999-12-16 | Sterix Limited | Pharmaceutical composition with tumor necrosis factor a and 2-methoxyestrone-3-o-sulphamate for inhibition of estrone sulphatase |
DE19712488A1 (en) * | 1997-03-25 | 1998-10-01 | Knoell Hans Forschung Ev | Steroid sulfamates, processes for their preparation and use thereof |
FR2772761B1 (en) * | 1997-12-23 | 2000-05-26 | Lipha | NOVEL N-PHENYLAMIDE AND N-PYRIDYLAMIDE DERIVATIVES, THEIR PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US6046186A (en) * | 1997-12-24 | 2000-04-04 | Sri International | Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use |
EP1065281A4 (en) | 1998-03-26 | 2004-08-18 | Kyowa Hakko Kogyo Kk | Method for searching steroid sulfatase inhibitors |
GB9807779D0 (en) | 1998-04-09 | 1998-06-10 | Ciba Geigy Ag | Organic compounds |
WO2000053620A1 (en) * | 1999-03-10 | 2000-09-14 | Nippon Organon K. K. | Novel estradiol derivatives |
DE19917930A1 (en) * | 1999-04-15 | 2000-10-19 | Schering Ag | Treating estrogen deficiency associated disorders, e.g. menopausal problems, osteoporosis, neoplasia or neurodegenerative disease, using new or known ent-steroids having bone-selective estrogenic activity |
JP5042411B2 (en) * | 1999-04-30 | 2012-10-03 | ステリックス リミテッド | Use of estrone derivatives as antitumor agents |
DE10006155B4 (en) * | 1999-06-24 | 2004-08-05 | Forschungszentrum Rossendorf E.V. | Process for the preparation of 16α- [18F] fluorestradiol sulfamates |
DK1237902T3 (en) * | 1999-12-13 | 2006-03-06 | Sterix Ltd | Halogenated sulphamate, phosphonate, thiophosphonate, sulfonate and sulfonamide compounds as inhibitors of steroid sulfatase |
HUP0300887A2 (en) * | 2000-01-14 | 2003-07-28 | Schering Aktiengesellschaft | Pharmaceutical compositions containing steroidal structures and uses thereof |
HUP0300335A2 (en) * | 2000-04-12 | 2003-07-28 | Schering Ag. | 8-betha-hydrocarbyl-substituted estratrienes as selective estrogens, their use and pharmaceutical compositions containing them |
GB0020498D0 (en) * | 2000-08-18 | 2000-10-11 | Sterix Ltd | Compound |
GB0113920D0 (en) * | 2001-06-07 | 2001-08-01 | Sterix Ltd | Composition |
WO2002100877A1 (en) * | 2001-06-11 | 2002-12-19 | Southwest Foundation For Biomedical Research | Novel 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity |
US8026229B2 (en) * | 2001-08-13 | 2011-09-27 | Sterix Limited | Antitumor-active 2-alkoxyestradiol sulfamates |
-
2000
- 2000-08-18 GB GBGB0020498.2A patent/GB0020498D0/en not_active Ceased
-
2001
- 2001-08-17 AU AU2001278629A patent/AU2001278629A1/en not_active Abandoned
- 2001-08-17 AU AU2001278638A patent/AU2001278638A1/en not_active Abandoned
- 2001-08-17 WO PCT/GB2001/003688 patent/WO2002016392A1/en active Application Filing
- 2001-08-17 EP EP01956712A patent/EP1311533A1/en not_active Withdrawn
- 2001-08-17 EP EP09002167A patent/EP2202240A1/en not_active Withdrawn
- 2001-08-17 WO PCT/GB2001/003705 patent/WO2002016394A1/en not_active Application Discontinuation
- 2001-08-17 EP EP01956710A patent/EP1311532B1/en not_active Expired - Lifetime
- 2001-08-17 WO PCT/GB2001/003692 patent/WO2002016393A1/en not_active Application Discontinuation
- 2001-08-17 AU AU2001278631A patent/AU2001278631A1/en not_active Abandoned
- 2001-08-17 JP JP2002521490A patent/JP5191079B2/en not_active Expired - Fee Related
- 2001-08-17 DK DK01956710T patent/DK1311532T3/en active
- 2001-08-17 PT PT01956710T patent/PT1311532E/en unknown
- 2001-08-17 EP EP01956719A patent/EP1311534A1/en not_active Withdrawn
- 2001-08-17 DE DE60138390T patent/DE60138390D1/en not_active Expired - Lifetime
- 2001-08-17 JP JP2002521489A patent/JP5074655B2/en not_active Expired - Fee Related
- 2001-08-17 AT AT01956710T patent/ATE428720T1/en active
- 2001-08-17 ES ES01956710T patent/ES2323630T3/en not_active Expired - Lifetime
- 2001-08-17 JP JP2002521488A patent/JP4958377B2/en not_active Expired - Fee Related
-
2003
- 2003-02-14 US US10/367,622 patent/US7067503B2/en not_active Expired - Fee Related
- 2003-02-14 US US10/367,114 patent/US7119081B2/en not_active Expired - Fee Related
-
2006
- 2006-03-03 US US11/368,367 patent/US8030296B2/en not_active Expired - Fee Related
-
2009
- 2009-06-09 CY CY20091100609T patent/CY1109130T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2002016392A1 (en) | 2002-02-28 |
CY1109130T1 (en) | 2014-07-02 |
EP1311534A1 (en) | 2003-05-21 |
JP4958377B2 (en) | 2012-06-20 |
JP5191079B2 (en) | 2013-04-24 |
US8030296B2 (en) | 2011-10-04 |
AU2001278629A1 (en) | 2002-03-04 |
WO2002016393A1 (en) | 2002-02-28 |
EP2202240A1 (en) | 2010-06-30 |
ATE428720T1 (en) | 2009-05-15 |
EP1311533A1 (en) | 2003-05-21 |
US20060281719A1 (en) | 2006-12-14 |
AU2001278638A1 (en) | 2002-03-04 |
DE60138390D1 (en) | 2009-05-28 |
JP5074655B2 (en) | 2012-11-14 |
US20030225051A1 (en) | 2003-12-04 |
GB0020498D0 (en) | 2000-10-11 |
JP2004506742A (en) | 2004-03-04 |
US7067503B2 (en) | 2006-06-27 |
ES2323630T3 (en) | 2009-07-22 |
JP2004511441A (en) | 2004-04-15 |
EP1311532B1 (en) | 2009-04-15 |
WO2002016394A1 (en) | 2002-02-28 |
DK1311532T3 (en) | 2009-06-22 |
JP2004506741A (en) | 2004-03-04 |
EP1311532A1 (en) | 2003-05-21 |
US20030203855A1 (en) | 2003-10-30 |
PT1311532E (en) | 2009-06-01 |
US7119081B2 (en) | 2006-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109130T1 (en) | Estrogen-17-Sulfamate as Steroid Sulfate Inhibitors | |
KR100322650B1 (en) | A pharmaceutical composition comprising a ring system compound for use to control oestrogen production | |
EP1042352A4 (en) | Androgenic steroid compounds and a method of making and using the same | |
ES2142773A1 (en) | Derivatives of isosorbid mononitrate, utilization as vasodilator agents with reduced tolerance | |
WO2002032409A3 (en) | Use of compound in the manufacture of a pharmaceutical for inhibiting steroid sulphatase and steroid dehydrogenase activity | |
AU3458997A (en) | Anti-beta-amyloid protein-induced cytotoxicity composition | |
ATE319734T1 (en) | STEROIDAL COMPOUNDS FOR INHIBITING STEROID SULFATASES | |
AU2190601A (en) | Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase | |
NZ509516A (en) | Silicon-containing linkers for nucleic acid mass markers | |
MX9706627A (en) | Optically active thiazolidinone derivatives. |